SMAD3 and hepatocellular carcinoma: It is reported that HEY2 binds to Smad3 and Smad4 promoters to inhibit the transcriptional activity of Smad3 and Smad4, and accelerates the malignant progression of hepatocellular carcinoma through TGF-β/Smad signaling pathway [43].